Alternative capsid strategies for targeting recombinant AAV gene therapy

Abstract

The advent of new serotypes of adeno-associated viruses (AAV) has expanded the tissue tropism and allowed clinically relevant numbers of cells to be transduced by rAAV vectors. The two most significant obstacles in the way of future gene therapies with AAV vectors are tissue/target cell specificity and sitel-specific integration. Other reviews contained in this issue will look at advances in site-specific integration. This review will focus on the latest developments in AAV vector tropism and tissue/ target cell specificity.